Thrombotic Microangiopathy Secondary to Sirolimus Monotherapy in Orthotopic Liver Transplant
Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor often used in clinical conjunction with calcineurin inhibitors (CNIs) or mycophenolate mofetil to prevent solid organ transplant rejection. While nephrotoxicity is a well-known side effect of CNIs, renal injury because of mTOR inhibitors...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
American College of Physicians
2024-06-01
|
| Series: | Annals of Internal Medicine: Clinical Cases |
| Online Access: | https://www.acpjournals.org/doi/10.7326/aimcc.2023.0960 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor often used in clinical conjunction with calcineurin inhibitors (CNIs) or mycophenolate mofetil to prevent solid organ transplant rejection. While nephrotoxicity is a well-known side effect of CNIs, renal injury because of mTOR inhibitors is exceedingly rare and limited to case reports, primarily in the setting of renal transplant and post-hematopoietic stem cell transplant. This case demonstrates a rare occurrence of sirolimus-induced thrombotic microangiopathy after orthotopic liver transplant. |
|---|---|
| ISSN: | 2767-7664 |